To determine whether a prior history of hepatosplenic candidiasis resulted in increased Candidaassociated morbidity and mortalii after marrow transplant, 15 consecutive patients with biopsy-proven hepatosplenic candidiasis were observed prospectively. All patients received amphotericin B before transplant. Amphotericin B was continued at a dose of 0.5 mg/kg/day from conditioning through marrow engraftment, at which time it was discontinued if computerized tomography (CT) evidence of disease was stable or improved. Patients were observed for progression of candidiasis for the first 100 days after transplant. The amount and duration of antifungal therapy received before transplant varied widely. The majority of patients (73%) had NVASIVE FUNGAL infections carry a high risk of mortality in the immunocompromised host, largely because of the difficulty in diagnosis and limited treatment options.'-' Hepatosplenic candidiasis is a clinical syndrome of invasive Candida infection that has attracted greater interest in the last several years.6-" The morbidity and mortality from invasive Candida infection is particularly high after marrow transplantation because of profound neutropenia and immunosuppression inherent in the procedure. In a recent review, hepatosplenic candidiasis was documented in approximately 4% of patients after marrow transplant, with a significant increase in incidence during the most recent years of the study.'.3 Overall mortality in this group of patients was 90%.
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Hepatosplenic candidiasis is also seen in patients receiving intensive chemotherapy for malignant diseases thought to be related to aggressive chemotherapeutic regimens, prolonged neutropenia, and the use of broad-spectrum antibiotic^.'^'^ Recently, an increasing number of cancer patients with a history of invasive fungal infection are being considered for marrow transplantation. It is unclear whether a pretransplant history of hepatosplenic candidiasis leads to increased Cundida-related morbidity and mortality in the posttransplant period and therefore should be considered a relative contraindication to transplantation. A case report in patients with leukemia has shown survival despite further intensive chemotherapy in the setting of a~pergillus'~ and, more recently, case reports of successful marrow transplantation after aspergillus infection have been encouraging that this approach can be successf~l.'~~'' To determine the outcome in patients with the pretransplant diagnosis of heapatosplenic candidiasis, we conducted a prospective study of consecutive patients who underwent transplantation with a history of proven hepatosplenic candidiasis. diagnosis. Hepatosplenic candidiasis was defined as a positive culture for Candida or fungal elements consistent with Candida (ie, budding yeasts or pseudohyphae) seen on histopathologic examination of liver or spleen biopsies. Also included were 2 patients with syndromes highly suggestive of visceral fungal involvement. One of these patients had a combination of candidemia and computerized tomography (CT) scans consistent with microabscesses of the liver and/or spleen and a liver biopsy showing granulomas but no hyphae1 elements or positive culture. The other patient had candidemia, CT lesions consistent with hepatosplenic candidiasis, and multiple skin lesions, one of which was biopsied and showed invasive candida1 organisms. The blood and skin biopsy were both culture positive for C tropicalis.
I

MATERIALS AND METHODS
Patients
Pretransplant evaluation and antifungal management follow-up.
Before transplant, clinical history, documentation of hepatosplenic candidiasis, results of prior CT scans, and total doses and duration of antifungal therapy were recorded. The patients also underwent CT or magnetic resonance imaging (MRI) evaluations to determine the effectiveness of prior therapy and to serve as baseline for subsequent posttransplant examinations. Patients were observed clinically from initial evaluation pretransplant through day 100 after transplant. Blood cultures were performed daily for fevers during the neutropenic period. In addition, patients had abdominal CT and/or MFU scans repeated as clinically indicated. All patients were treated with amphotericin B at a dose of 0.5 mgkg from the onset of conditioning for transplant until engraftment, defined as 2 consecutive days with an absolute neutrophil count of 2500/pL, was established. At the time of engraftment, amphotericin B was discontinued after 1 to 2 weeks only if patients were clinically asymptomatic and had stable or resolving lesions on CT. Duration of therapy was prolonged in some cases because of questions about stabilization of disease. Abbreviations: VOD, veno-occlusive disease of the liver; CMV, cytomegalovirus.
Endpoints of the study included (1) culture or histopathologic evidence o f invasive candidal infection after transplant; (2) evolution of disease as seen on CT or MRI scans; (3) clinical outcome, including death; and (4) amount and duration o f antifungal therapy. Every effort was made to obtain autopsies on patients not surviving 100 days after transplant. Data on patients surviving greater than 100 days after transplant were included when available.
RESULTS
Patients.
During this period of time, 463 transplants were performed, so the study group of 15 represented 3% of patients undergoing transplant during this period. Underlying diagnoses included acute myelogenous leukemia in relapse (N = 9), acute lymphocytic leukemia in remission (N = 4) or relapse (N = l), and chronic myelogenous leukemia (N = 1). Patients underwent HLA-matched (N = 11) or mismatched (N = 2) transplant and 11 experienced acute graftversus-host disease (GVHD) in the early posttransplant period. Two patients underwent autologous transplant.
Diagnosis of hepatosplenic candidiasis before transplant and clinical outcome. The diagnosis of candida infection was made by liver biopsy in 13 patients, splenectomy in 1 patient, and biopsy of skin lesions plus a positive blood culture for C tropicalis and consistent abdominal CT scan in 1 patient. All patients had CT evidence consistent with hepatosplenic candida with liver lesions only in 6 patients, liver plus spleen lesions in 6, splenic involvement only in 1, and liver plus renal involvement in 2. Blood cultures were positive in only 5 of 15 cases, including C tropicalis in patients no. l , 2, and 3; C albicans in patient no. 9; and C paratropicalis in patient no. 14. There were 7 deaths (47%) BJERKE, MEYERS, AND BOWDEN and 8 survivors (53%) by day 100 after transplant (Table 1) . Autopsies were obtained on 5 of the 7 patients who died. The deaths of patients no. 9 and 10 were directly related to fungal disease. Of note. is that patient no. 9 developed C tropicalis fungemia before death, different than the species C albicans that was grown from his blood cultures before transplant. He was also found to have disseminated aspergillosis and no signs of marrow engraftment 17 days after an autologous transplant. Patient no. 10 had shown no clinical signs of active fungal disease until approximately day 60 after marrow transplant. At that time, she became persistently neutropenic for unclear reasons and developed C glabruta fungemia and was not on amphotericin B at the time. She was found to have disseminated candidal disease on autopsy in addition to disseminated aspergillosis. Importantly, it is not clear that either of these patients failed their pretransplant therapy because both had evidence for infections with new fungal organisms after transplant, one while not receiving amphotericin B.
Three of the remaining autopsied patients died of primary causes other than fungal disease (Table l) , with autopsies showing fungal abscesses in patient no. 11 who died of acute bacterial sepsis, resolving abscesses without fungal elements seen in patient no. 12, and no signs of fungal disease in patient no. 13. Autopsies were denied on 2 patients (no. 14 and 15). Neither patient was thought to have had clinical signs of fungal disease at the time of death.
Eight of 15 patients (53%) survived greater than 100 days after transplant ( Table 2 ) and exhibited no clinical signs of fungal infection. Three patients continue to be alive and well. The remaining 5 patients have died of leukemic relapse without clinical signs of fungal infection noted before death. (Table 3) . In general, initiation of antifungal therapy was based on the previous history and on evaluation of pretransplant CT scans. During this pretransplant period, patients with scans showing apparent resolution of fungal disease received amphotericin B after 3 to 4 days of neutropenic fever unresponsive to broad-spectrum antibiotic therapy. Those having previously received greater than 2 g of amphotericin B with stable or improved (but not normal) CT scans received amphotericin B with the onset of neutropenia. Patients with newly diagnosed hepatosplenic candidiasis (found on evaluation immediately preceding transplant) or those found to have progression of lesions on CT scans, received amphotericin B and 5-flucytosine (5-FC) as soon as they were identified. 5-FC was administered at a dose of 150 mgkg before transplant. Dose adjustments were made to keep the peak serum concentrations between 50 and 100 p g l d . Patients receiving amphotericin B at the time of admission to Seattle (N = 7) tolerated ongoing amphotericin B therapy without significant change in their renal function throughout the preengraflment period. All 8 patients who were restarted on amphotericin B at the time of conditioning tolerated the drug with not more than a 50% increase in baseline creatinine levels during the therapy period.
Rudiographicjndings. All the patients had pretransplant abdominal CT scans that showed hypodense lesions, with 7 patients showing lesions in the liver only, 1 in the spleen only, and 7 in multiple organs. Comparisons of scans obtained before and after transplant are shown ( Table 3) . Two patients did not have scans performed after transplant. One patient died 17 days after transplant with disseminated fungal disease. The other patient survived greater than 100 days after transplant, eventually dying of persistent leukemia without clinical signs of fungal disease. No patient who underwent a CT scan after transplant showed signs of progression of CT lesions after transplant.
DISCUSSION
This study shows that patients with documented hepatosplenic candidiasis can successfully undergo marrow transplant when they receive antifungal therapy before the time of conditioning and through the pre-engraftment period. Of the 15 patients who underwent marrow transplantation with a history of proven hepatosplenic candidiasis, only 3 died with any evidence of fungal disease. Two of these patients died with Candida (one with a different species than prediagnosis) in addition to disseminated Aspergillus. The latter patient died while no longer receiving amphotericin B. We compare these results with our retrospective experience of 1,506 transplants, in which 171 patients had invasive candidal infection.' The demographics of this group were similar to the demographics of the patients in this study: the majority underwent allogeneic matched transplant, age and sex were comparable, and the majority of patients reveived transplants for acute myelogenous leukemia in both the present and this historical group. The mortality of patients with liver/spleen/renal disease was 75%. Our success in treating this infection did not appear to differ by underlying disease type, remission status at the time of transplant, or in the autologous transplant patients compared with allogeneic transplant patients.
Infections with multiple fungal species were observed both in this and our retrospective study and may suggest an underlying cellular defect, possibly in macrophage function. It is possible that macrophage colony-stimulating factorI7 or other growth factors may have been of some benefit. It is known that patients with GVHD often have a multiple opportunistic infection, presumably related to the underlying Tcell defects associated with GVHD or its treatment.
There may be several explanations that could account for the comparatively good outcome in this study. The most likely explanation is that, because candidal disease was recognized and treated before commencing myeloablative therapy, control or cure was achieved before transplant. The type of pretransplant therapy required to achieve this outcome remains undefined because every patient was treated differently. This difference was due in part to the lack of standardized guidelines available for treatment of hepatosplenic Cundida in this group of patients. There is considerable evidence that the prognosis of hepatosplenic candidiasis is greatly influenced by early recognition and prompt initiation of systemic antifungal the rap^.^"' Although hepatosplenic candidiasis is thought to be a chronic syndrome, it may progress to acute infection when a patient's immune status becomes severely compr~mised,~.~ presumably because not all viable fungus was eliminated. Therefore, some investigators feel that the complete eradication of visceral foci of Candida is essential before proceeding with severe immunosuppressive regimens.' Ongoing suppression with amphotericin B during the pre-engraftment period until recovery of granulocyte and lymphocytes necessary to maintain control and ultimately to eradicate could explain the favorable outcome observed here.
It is possible that fluconazole may also have been a good alternative therapy for these patients, particularly for the 2 patients who had evidence of progressive disease while on Amphotericin B. Several studies have now shown fluconazole to be effective prophylaxis in this and studies in neutropenic cancer patients have shown a good outcome in patients failing to respond to amphotericin B.*'." Fluconazole also has the advantage of sparing renal toxicity, a common problem with the administration of amphotericin B. Alternatively, one of the lipid complexed amphotericin B products may allow delivery of higher amphotericin B doses with less nephrotoxicity.'' Assessing the state of infectivity of Candida in patients receiving antifungal therapy is often difficult. Shirkhoda reported several patients with a diagnosis of hepatosplenic candidiasis who showed persistent liver lesions on CT scan For personal use only. on September 14, 2017. by guest www.bloodjournal.org From after prolonged courses of antifungal therapy." Open-liver biopsy showed fibrotic nodules without evidence of fungal elements. Thaler et alZ3 has shown in an animal model that calcified lesions seen on CT scan are actually dead fungal elements. Although CT has proved to be a sensitive tool in the diagnosis of visceral candidiasis, it lacks specificity in assessing the treatment outcome. Our experience in the marrow transplant setting appears to be consistent with these experiences.
Most patients had improvement in their CT scans during the 100-day follow-up period. Nine of 11 patients who underwent transplantation with abnormal CT scans showed improvement of lesions after transplant. However, only 2 patients showed total resolution of CT lesions after transplant, including 1 patient who showed progression of disease on scans before transplant. Whereas no patient had scans that showed progression of disease after transplant, the number of patients with total resolution of CT scan abnormalities was low.
In conclusion, it appears that a history of hepatosplenic candidiasis should not be considered an absolute contraindication to marrow transplantation. It might be pointed out that the survival of leukemic patients in relapse is generally poor, with death being due either to relapse or infection. Therefore, improvement in management of hepatosplenic Candida may have a significant impact on mortality in this group of patients. This observation suggests that patients with stable or improving hepatosplenic candidiasis can safely undergo marrow transplantation after receiving amphotericin B therapy before conditioning throughout the period of neutropenia, with discontinuation of therapy based on clinical, laboratory, and CT scan findings. Patients with progressive infection may benefit from alternative therapy such as fluconazole or one of the lipid-complexed amphotericin products.
